TY - JOUR
T1 - Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection
AU - Beuschlein, Felix
AU - Weigel, Jens
AU - Saeger, Wolfgang
AU - Kroiss, Matthias
AU - Wild, Vanessa
AU - Daffara, Fulvia
AU - Libé, Rosella
AU - Ardito, Arianna
AU - Ghuzlan, Abir Al
AU - Quinkler, Marcus
AU - Oßwald, Andrea
AU - Ronchi, Cristina L.
AU - De Krijger, Ronald
AU - Feelders, Richard A.
AU - Waldmann, Jens
AU - Willenberg, Holger S.
AU - Deutschbein, Timo
AU - Stell, Anthony
AU - Reincke, Martin
AU - Papotti, Mauro
AU - Baudin, Eric
AU - Tissier, Frédérique
AU - Haak, Harm R.
AU - Loli, Paola
AU - Terzolo, Massimo
AU - Allolio, Bruno
AU - Müller, Hans Helge
AU - Fassnacht, Martin
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background: Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection occurs frequently. Objective: The aim of this study was to identify markers with prognostic value for patients in this clinical setting. Design, Setting, and Participants: From the German ACC registry, 319 patients with the European Network for the Study of Adrenal Tumors stage I-III were identified. As an independent validation cohort, 250 patients from three European countries were included. Outcome Measurements and Statistical Analysis: Clinical, histological, and immunohistochemical markers were correlated with recurrence-free (RFS) and overall survival (OS). Results: Although univariable analysis within the German cohort suggested several factors with potential prognostic power, upon multivariable adjustment only a few including age, tumor size, venous tumor thrombus (VTT), and the proliferation marker Ki67 retained significance. Among these, Ki67 provided the single best prognostic value for RFS (hazard ratio [HR] for recurrence, 1.042 per 1% increase; P <.0001) and OS (HR for death, 1.051; P <.0001) which was confirmed in the validation cohort. Accordingly, clinical outcome differed significantly between patients with Ki67
AB - Background: Recurrence of adrenocortical carcinoma (ACC) even after complete (R0) resection occurs frequently. Objective: The aim of this study was to identify markers with prognostic value for patients in this clinical setting. Design, Setting, and Participants: From the German ACC registry, 319 patients with the European Network for the Study of Adrenal Tumors stage I-III were identified. As an independent validation cohort, 250 patients from three European countries were included. Outcome Measurements and Statistical Analysis: Clinical, histological, and immunohistochemical markers were correlated with recurrence-free (RFS) and overall survival (OS). Results: Although univariable analysis within the German cohort suggested several factors with potential prognostic power, upon multivariable adjustment only a few including age, tumor size, venous tumor thrombus (VTT), and the proliferation marker Ki67 retained significance. Among these, Ki67 provided the single best prognostic value for RFS (hazard ratio [HR] for recurrence, 1.042 per 1% increase; P <.0001) and OS (HR for death, 1.051; P <.0001) which was confirmed in the validation cohort. Accordingly, clinical outcome differed significantly between patients with Ki67
UR - http://www.scopus.com/inward/record.url?scp=84924955633&partnerID=8YFLogxK
U2 - 10.1210/jc.2014-3182
DO - 10.1210/jc.2014-3182
M3 - Article
C2 - 25559399
AN - SCOPUS:84924955633
SN - 0021-972X
VL - 100
SP - 841
EP - 849
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 3
ER -